NIFK-AS1: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: NIFK-AS1

NCBI ID: G254128

NIFK-AS1

Other Name(s): NIFK-AS1 variant 3 | NIFK antisense RNA 1 | NIFK-AS1 variant 1

NIFK-AS1: A Protein Target for Cancer and Neurodegenerative Diseases

NIFK-AS1 (NIFK-AS1 variant 3) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and liver. It is a key regulator of the immune response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified NIFK-AS1 as a potential drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NIFK-AS1 has been shown to play a role in the development and progression of these diseases, and may be a useful target for the development of new treatments.

One of the key reasons for the potential of NIFK-AS1 as a drug target is its role in the immune response. NIFK-AS1 is a key regulator of the activation and proliferation of natural killer cells, which are a crucial part of the immune system. NIFK-AS1 has been shown to play a role in the regulation of natural killer cell function, and may be a useful target for the development of immune-based therapies.

In addition to its role in the immune system, NIFK-AS1 has also been shown to be involved in the regulation of cell growth and differentiation. NIFK-AS1 has been shown to play a role in the regulation of cell proliferation and has been implicated in the development of cancer.

Another potential use of NIFK-AS1 as a drug target is its role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the blood and helps to protect the brain from harmful substances. NIFK-AS1 has been shown to play a role in the regulation of the blood-brain barrier, and may be a useful target for the development of drugs that can bypass this barrier and reach the brain.

In addition to its potential as a drug target, NIFK-AS1 has also been shown to be a potential biomarker for a number of diseases. NIFK-AS1 has been shown to be expressed in a variety of tissues and has been used as a biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, NIFK-AS1 is a protein that has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a drug target or biomarker makes it an attractive target for the development of new treatments. Further research is needed to fully understand the role of NIFK-AS1 in these diseases and to develop effective treatments.

Protein Name: NIFK Antisense RNA 1

The "NIFK-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIFK-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets